ALEBUND ( 09637) CEO Xia Guoyao stated that focusing on innovative drugs for kidney disease is the differentiated positioning of ALEBUND compared to other biopharmaceutical companies. In the next five years, the company will continue to focus on the kidney disease field, with its core product AP301 set to submit a listing application to the China National Medical Products Administration, expected to be approved for listing next year.

Regarding AP301, COO Zhang Huading revealed that a consensus has been reached with regulatory authorities on the listing submission plan, and the listing application will be submitted soon, with approval expected by the end of next year. The company has also initiated preparations for the drug's market launch, including production capacity and future medical insurance pricing negotiation strategies.

ALEBUND has a factory in Yangzhou, Jiangsu, which can support an annual production capacity of 200 tons for AP301.

In addition, AP301 is advancing through Phase III clinical trials in the United States, with plans to be listed in the U.S. by 2028.

ALEBUND began its public offering last Thursday (18th), with a minimum subscription of 100 shares and an entry fee of approximately HKD 2,283. Currently, 16 brokers have collectively lent HKD 5.1 billion in margin financing, which is 39 times oversubscribed compared to the public offering fundraising amount of HKD 128 million